IP Library › Granted Patent US 9,868,757
Granted Patent B2
US 9,868,757 · App. 14/931,083 · Granted Jan 16, 2018

5-β, 14-β-androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure

Inventors: Patrizia Ferrari (Varese, IT); Giuseppe Bianchi (Milan, IT); Mara Ferrandi (Milan, IT)
Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
C07J17/00C07J41/0038C07J43/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,868,757
App. No.
14/931,083
Granted
Jan 16, 2018
Kind
B2
Abstract

Compound of formula (I), wherein the symbol have the meaning reported in the text; for preparing a medicament for the prevention and/or treatment of proteinuria, glomerulosclerosis or renal failure.

Claims (24)

1. A method for treating proteinuria, comprising the step of administering to a normotensive patient in need thereof a therapeutically effective amount of a compound of formula (I),

wherein:

the symbol represents a single bond;

Y is OR 4 and has an alpha or a beta configuration;

R is 3-furyl;

R 1 is hydrogen;

R 2 is hydrogen;

R 3 is hydrogen;

R 4 is hydrogen.

2. The method according to claim 1 , wherein the compound is administered in a dose of from 0.05 mg to 20 mg per day.

3. The method according to claim 2 , wherein the compound is administered in a dose of from 0.5 mg to 15 mg.

4. The method according to claim 3 , wherein the compound is administered in a dose of from 5 mg to 10 mg.

5. The method according to claim 4 , wherein the compound is administered) in a single dose schedule.

6. The method according to claim 4 , wherein the compound is administered in a multiple dose schedule.

7. The method according to claim 1 , wherein the compound is administered to the patient orally, intravenously, intramuscularly, intra-arterially, intramedullary, intrathecally, intraventricularly, transdermally, transcutaneously, subcutaneously, intraperitoneally, intranasally, enterally, topically, sublingually or rectally.

8. A method of antagonizing podocyte protein loss in a normotensive patient in need thereof, which comprises administering to said patient a therapeutically effective amount of a compound of formula (I),

wherein:

the symbol represents a single bond;

Y is OR 4 and has an alpha or a beta configuration;

R is 3-furyl;

R 1 is hydrogen;

R 2 is hydrogen;

R 3 is hydrogen;

R 4 is hydrogen.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2026
From: CVIE THERAPEUTICS LIMITED
To: SEISMIC PHARMACEUTICALS OPERATIONS LLC
Reel/Frame 073612/0297 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2018
From: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.; ROSTAQUO S.P.A.
To: CVIE THERAPEUTICS LIMITED
Reel/Frame 045210/0038 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2015
From: FERRARI, PATRIZIA; BIANCHI, GIUSEPPE; FERRANDI, MARA
To: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
Reel/Frame 036947/0775 →
Priority Claims (1)
EP 09155834 · Mar 23, 2009 · regional
Continuity (2)
Continuation 13258728
Related Publication 20160251392A1 · Sep 1, 2016